Home›Stock Screener›Alivus Life Sciences›Financial Statements

Alivus Life Sciences Complete Financial Statements

9 Years of Data
2026 - 2018

In FYNone, Alivus Life Sciences (ALIVUS) reported revenue ₹2,664 Cr, net profit ₹603 Cr and EPS ₹49.10, with a net profit margin of 21.6% and ROE of 17.0%. Full financial statements from FY2018 to FY2026 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Compare with ALIVUS DCF valuation to assess whether the stock is under or overvalued.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 21.63% 2026 data
EBITDA Margin 32.85% 2026 data
Operating Margin 31.00% 2026 data
Return on Assets 14.19% 2026 data
Return on Equity 16.96% 2026 data

Balance Sheet Ratios

Current Ratio 18.52 2026 data
Equity Ratio 83.66% 2026 data
Asset Turnover 0.66 2026 data

ALIVUS Revenue, Net Profit & EBITDA — Year-on-Year Growth

ALIVUS YoY (March 2026 vs Period) — revenue +2.0%, net profit +6.7%, EBITDA +3.1%, expenses +1.4%.

Revenue Growth
+2.0%
Year-over-Year
Net Profit Growth
+6.7%
Year-over-Year
EBITDA Growth
+3.1%
Year-over-Year
Expense Growth
+1.4%
Year-over-Year
Assets Growth
+16.8%
Year-over-Year
Equity Growth
+18.3%
Year-over-Year
Operating Cash Flow Growth
+44.1%
Year-over-Year
Investing Cash Flow Growth
+7.5%
Year-over-Year
Financing Cash Flow Growth
-966.7%
Year-over-Year

ALIVUS Income Statement — Revenue, EBITDA & Net Profit

Alivus Life Sciences revenue ₹2,664 Cr, EBITDA ₹885 Cr, net profit ₹603 Cr, EPS ₹49.10 (None) — net profit margin 21.6%. For live price, earnings ratios and company overview, see ALIVUS stock price BSE.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018
Revenue 2,664 2,612 2,421 2,295 2,190 2,138 1,886 1,549 887 0
Expenses 1,779 1,755 1,704 1,609 1,519 1,507 1,294 1,065 639 0
EBITDA 885 858 717 686 671 631 592 484 248 0
Operating Profit Margin % 31.00% 31.00% 29.00% 30.00% 30.00% 29.00% 31.00% 31.00% 28.00% -5.00%
Depreciation 79 75 61 54 42 38 33 29 19 0
Interest 5 5 2 2 1 28 88 34 1 0
Profit Before Tax 801 751 654 631 629 565 471 421 228 0
Tax 195 187 169 160 162 146 119 108 33 0
Net Profit 603 565 486 471 467 419 352 313 196 0
Earnings Per Share (₹) 49.10 45.99 39.63 38.43 38.11 35.63 32.61 29.04 24.64 -7.89

ALIVUS Balance Sheet — Assets, Liabilities & Shareholders' Equity

ALIVUS total assets ₹3,983 Cr, total equity ₹3,332 Cr, total liabilities ₹ Cr (2026) — ROE 17.0%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018
ASSETS
Total Assets 3,983 3,411 2,850 2,702 2,471 1,997 1,726 1,475 0
Current Assets 2,649 2,335 1,916 1,850 1,765 1,399 1,160 931 0
Fixed Assets 1,038 955 805 781 595 573 546 456 0
Capital Work in Progress 284 102 106 62 92 14 11 80 0
Investments 781 478 0 0 0 0 0 0 0
Other Assets 1,881 1,877 1,939 1,860 1,784 1,410 1,169 939 0
LIABILITIES
Total Liabilities
Current Liabilities 143 124 79 67 33 23 16 7 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 3,332 2,817 2,332 2,138 2,054 753 402 88 -1
Share Capital 25 25 25 25 25 2 2 2 0
Reserves & Surplus 3,308 2,793 2,308 2,114 2,030 751 400 86 -1

ALIVUS Cash Flow Statement — Operating, Investing & Financing

Alivus Life Sciences operating cash flow ₹565 Cr, investing ₹-570 Cr, financing ₹-64 Cr, net cash flow ₹-69 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018
Operating Activities 565 392 414 306 598 388 195 10 -1
Investing Activities -570 -616 -117 -147 -122 -69 -51 -9 0
Financing Activities -64 -6 -279 -388 -79 -214 -137 1 1
Net Cash Flow -69 -230 18 -228 397 106 8 2 0